Wendel Bruce 4

What Happened
Wendel Bruce, a director of ImmunityBio, received an award of 65,600 shares (reported as a derivative grant) on June 9, 2026. The grant was issued at $0.00 (no cash paid) and is reported as an award/derivative acquisition rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-09; Form 4 filed 2026-06-10 (timely).
• Transaction type/code: A (Award/Grant of derivative shares).
• Shares granted: 65,600; grant reported at $0.00 (no purchase price).
• Shares owned after transaction: Not specified in the filing.
• Vesting footnote: Footnote F1 — 100% of the shares vest on the earlier of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders, provided Bruce remains a Service Provider under the company’s 2025 Equity Incentive Plan.
• No 10b5-1 plan, tax-withholding sale, or immediate sale noted in the filing.

Context
This was a compensation-related share award (derivative grant) rather than market buying or selling; such grants are common for directors and reflect equity-based compensation subject to service-conditional vesting. Because no cash changed hands and the shares are subject to time/service vesting, the grant does not indicate an immediate change in selling pressure or insider liquidity.